| ||Ms. Ann Horan (MAFC, FCCA, FIB) is Chairman of HPRA. Prior to this role, she was CEO of the DCU Ryan Academy for Entrepreneurs. Ann’s career includes senior executive roles in regulation, banking, small business and education. She served on boards including Dublin City University, the Institute of Bankers, South Dublin Chamber of Commerce and chaired associations including the UK based Factors & Discounters Association and the International Women’s Forum. Through her successful career, she developed expertise in the areas of leadership, strategic planning, financial control, risk management, technology and corporate governance. She has proven ability to operate in both the public and private sectors and has direct experience in the areas of regulation and investment management. Ann is an accountant with a Masters in Finance from DCU. |
Mr. Pat Brangan (MVB, MRCVS) is a retired Senior Superintending Veterinary Inspector of the Department of Agriculture, Food and Marine (DAFM). He qualified from Trinity College, Dublin in 1972 and spent fifteen years in general veterinary practice prior to joining the Department. Whilst with the Department he was involved in the veterinary medicines area in regard to policy, regulation and the implementation of European and national legislation. Dr. Brangan is currently a course presenter in FETAC approved training for Responsible Persons in Licensed Merchants premises licensed by the DAFM. He is Chairman of the Scientific Advisory Committee on Doping and Medication Control of the Irish Greyhound Board. Along with his role as Chairman of the Advisory Committee Veterinary Medicines, he is also Chairman of the Audit and Risk Committee of the HPRA and is a past member of The Poisons Council of Ireland.
| || ||Mr. Wilfrid J. Higgins (BE, MBA, MSc, CEng, FIEI) was a CEN (Comité Européen de Normalisation) Consultant for Medical Devices and was previously Principal Engineering Advisor in the HSE and formerly in the Department of Health (DoH). He has worked in the pharmaceutical industry as well as the consulting engineering and hospital sectors in the application and procurement of engineering systems, medical technology and the regulation of medical devices. He has represented the DoH at EU Council meetings and the EU Medical Devices Expert Group. Along with his role as Chairman of the Advisory Committee Medical Devices of the HPRA he is Chairman of the National Standards Authority Ireland (NSAI) Health Care Standards Committee and member of the ETCI TC10 Committee. He is an Adjunct Assistant Professor in the Department of Mechanical Engineering, Trinity College Dublin for medical device regulation, standards & risk analysis. |
| || || |
Mr. David Holohan (BCOMM, MBA, APA, C Dir, M.Inst.D, CMgr FCMI, Chartered FCSI) is Chief Investment Officer at Merrion Capital and was appointed to the Board of the HPRA by the Minister for Health in January 2016. Before joining Merrion in 2010, he was a Partner at a Dublin based investment firm and previously worked for a multi-billion dollar European hedge fund situated in London. David holds a Bachelor of Commerce degree from University College Dublin and an MBA with merit from Imperial College London. He is a Chartered Director (UK) and Member of the Institute of Directors (Ireland). David is also a Chartered Fellow of the Chartered Institute for Securities & Investment (UK) and a Chartered Fellow of the Chartered Management Institute (UK). David is Chairman of the Governing Body of IADT and is a Member of the National Oversight and Audit Commission (NOAC). He is also Non-Executive Chairman of the charity, One in Four. David is regularly cited for his business and investment opinions by both Irish and international media.
| || |
Mr. Brian Jones BS.c (Hons) is Director of Finance with Europe’s largest Jewish Primary School, based in London, and was appointed to the Board of the HPRA by the Minister for Health in January 2016. Prior to joining the school, he spent 7 years working at a senior level within Public Health. Brian is an experienced board member, holding roles with a number of organisations. He has previously lectured on the subject of Corporate Governance and has been invited to comment on emerging policy and had articles published on the subject a number of times.
| || ||Dr. Elizabeth Keane (MB, MPH, FFPHMI) was first appointed to the Board of the HPRA by the Minister for Health in November 2012. A consultant in Public Health Medicine, Dr. Keane is Adjunct Professor of Epidemiology and Public Health in UCC. Dr. Keane worked in hospital medicine for 5 years prior to undertaking a Masters in Public Health in UCD and completed Higher Specialist Training in Public Health Medicine in 1989. She was appointed the first Director of Public Health for Cork and Kerry in 1995. Dr. Keane is a fellow and Vice Dean of the Faculty of Public Health Medicine of the RCPI, a Convenor and Examiner of the Membership Examinations and Chair of the Education and Examinations Committee. She is a former Chair of both the National Cancer Registry Board and the Board of the National Disease Surveillance Centre (now HPSC). She has also served on the boards of the Irish Blood Transfusion Service and the Interim Health Information and Quality Authority. Dr. Keane’s main areas of interest include health status epidemiology health protection the public health aspects of blood borne viruses and international health regulations. |
| || ||Professor Caitriona O’Driscoll (BSc Pharm., PhD, MPSI), first Professor of Pharmaceutics, School of Pharmacy, University College Cork since 2003. Professor O’Driscoll served as Head of the School from 2003-09 and is currently Acting Head of the School. Professor O’Driscoll completed her PhD in Pharmaceutics at the University of Dublin, Trinity College, Ireland. She held the post of senior lecturer in Pharmaceutics at Trinity College until 2003. Professor O’Driscoll is a Council member of the Pharmaceutical Society of Ireland. Research interests include the design of drug delivery systems which exploit the physiological environment and utilise cell specific targeting to overcome the barriers to absorption. Candidate drugs include macromolecules, peptides/proteins, genes and poorly water-soluble compounds. Delivery systems of interest are: lipid-based vehicles and non-viral gene delivery systems employing modified cyclodextrins, nanoparticles and receptor-ligand mediated targeting. |
| || ||Dr. Diarmuid Quinlan (MB, BCh, BAO, BSc, MICGP, MRCGP, DFFP, DCH, DPD) works full time as a GP in Glanmire, Co. Cork. He is a graduate of UCC, completed specialist training in General Practice in Kent, England and then worked in Australia prior to returning to Cork. He currently chairs Diabetes in General Practice, a diabetes charity. He was appointed as clinical lead for Diabetes in HSE South, as chair of HSE South Diabetes service implementation group and to the national Diabetes Clinical Advisory Group in 2009. He is on the Cork committee of the Southdoc out-of-hours service. He is an accredited risk advisor in primary care, with the Medical Protection Society. He won the ICGP 2013 Quality in Practice award for ‘Methotrexate: We can do better: a novel approach to safer use of toxic medication’. He is an undergraduate tutor in UCC and an online dermatology tutor for Cardiff University, Wales. He writes regular columns for a number of publications. |